Table 3.
Results of group-wise radiomic feature-based classifications for molecular breast cancer subtypes using linear discriminant analysis and leave-one-out cross validation.
| HER2 Negative | Luminal A | Luminal B | HER2-Enriched | TN | All Others | |
|---|---|---|---|---|---|---|
| HER2 positive | 67.7% | - | - | - | - | 67.7% |
| Luminal A | - | - | 52.6% | 56.7% | - | - |
| Luminal B | - | 52.6% | - | 57.9% | 38.7% | 58.2% |
| HER2-enriched | - | 56.7% | 57.9% | - | 70.3% | 54.9% |
| TN | - | - | 38.7% | 70.3% | - | - |
| All others | 67.7% | - | 58.2% | 54.9% | - | - |
Note: HER2, human epidermal growth factor receptor 2; TN, triple negative.